Oncology Today with Dr Neil Love
407 episodes — Page 2 of 9
S25 Ep 185Immune Thrombocytopenia — ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here.
S25 Ep 184Urothelial Bladder Cancer — Microlearning Activity 1 with Dr Terence Friedlander: ESMO Congress 2025 Review
Dr Terence Friedlander discusses the selection and sequencing of therapy for patients with bladder cancer and reviews clinical findings recently presented at the 2025 ESMO Congress.CME information and select publications here.
S25 Ep 183Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.
S25 Ep 182Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium
Dr Jaffer Ajani from The University of Texas MD Anderson Cancer Center in Houston, Dr Rutika Mehta from Weill Cornell Medicine/NewYork-Presbyterian Hospital in New York, New York, Dr John Strickler from Duke University in Durham, North Carolina, and Dr Samuel Klempner from Massachusetts General Hospital in Boston review relevant data supporting immunotherapy for patients with gastroesophageal cancers and review recently presented clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium.CME information and select publications here.
S25 Ep 181Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review
Dr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025.CME information and select publications here.
S25 Ep 180HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium
Dr Haley Ellis from Harvard Medical School in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA School of Medicine in Los Angeles, California, and moderator Dr Lionel KankeuFonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data surrounding the management of HER2-positive GI cancers, alongside their perspectives on its clinical application and management.CME information and select publications here.
S25 Ep 179Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Seth Wander from Massachusetts General Hospital in Boston discuss real-world cases and recent clinical data surrounding the management of HR-positive breast cancer.CME information and select publications here.
S25 Ep 178Metastatic Bladder Cancer — Rapid Case Review Issue 1
Dr Catherine Fahey from the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Fern Anari from the Fox Chase Cancer Center in Philadelphia, Pennsylvania, present real patient cases on metastatic bladder cancer, with additional commentary from Dr Matthew Galsky from The Tisch Cancer Institute in New York, New York.CME information and select publications here.
S25 Ep 177Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review
Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.
S25 Ep 176Relapsed/Refractory Multiple Myeloma — ASH 2025 Review
Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting.CME information and select publications here.
S25 Ep 175HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
Prof Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E Krop from Yale Cancer Center, Dr Nancy U Lin from Dana-Farber Cancer Institute and Dr Joyce O’Shaughnessy from Baylor University Medical Center discuss real-world cases and recent clinical data pertinent to the management of HER2-positive breast cancer. CME information and select publications here.
S25 Ep 174Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-cell lymphoma.CME information and select publications here.
S25 Ep 173Colorectal Cancer — 5-Minute Journal Club Issue 2 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer. CME information and select publications here.
S25 Ep 172Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofibrosis and systemic mastocytosis.CME information and select publications here.
S25 Ep 171Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.CME information and select publications here.
S25 Ep 170Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH Annual Meeting.CME information and select publications here.
S25 Ep 169Colorectal Cancer — 5-Minute Journal Club Issue 1 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Dr Scott Kopetz from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of colorectal cancer.CME information and select publications here.
S25 Ep 168Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical application.CME information and select publications here.
S25 Ep 167Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases
Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.CME information and select publications here.
S25 Ep 166Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2
Dr Yelena Janjigian from Memorial Sloan Kettering Cancer Center in New York, New York, discusses updates across the treatment landscape for gastroesophageal cancers, as well as real-world clinical case examples.CME information and select publications here.
S25 Ep 165Urothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual Meeting
Dr Terence Friedlander from the UCSF Helen Diller Family Comprehensive Cancer Center and Dr Rana R McKay from the UC San Diego Moores Cancer Center summarize the treatment landscape for prostate and urothelial bladder cancer and discuss the implications of clinical findings recently presented at the ESMO Congress 2025.CME information and select publications here.
S25 Ep 164Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. CME information and select publications here.
S25 Ep 163Gastroesophageal Cancers — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr Manish A Shah from Weill Cornell Medicine in New York, New York, summarizes the treatment landscape and reviews relevant clinical datasets for patients with gastroesophageal cancers. CME information and select publications here.
S25 Ep 162Ovarian Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr Gottfried E Konecny from the University of California, Los Angeles, summarizes the treatment landscape and reviews relevant clinical datasets for patients with ovarian cancer. CME information and select publications here.
S25 Ep 161Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. CME information and select publications here.
S25 Ep 160Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.CME information and select publications here.
S25 Ep 159CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here.
S25 Ep 158HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer. CME information and select publications here.
S25 Ep 157Breast Cancer — Highlights from the 2025 ESMO Annual Meeting
Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss the implications of clinical findings in breast cancer recently presented at the 2025 ESMO Annual Meeting. CME information and select publications here.
S25 Ep 156Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
S25 Ep 155Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy. CME information and select publications here.
S25 Ep 154Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
S25 Ep 153Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen receptor degraders for the management of metastatic breast cancer. CME information and select publications here.
S25 Ep 152Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025. CME information and select publications here.
S25 Ep 151HER2-Positive Gastrointestinal Cancers — Clinical Investigator Perspectives on Actual Patient Cases
Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor summarize the treatment landscape and review key datasets in consideration of HER2-directed therapies for patients with HER2-positive gastrointestinal cancers. CME information and select publications here.
S25 Ep 150HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer. CME information and select publications here.
S25 Ep 149Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.
S25 Ep 148ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs
Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here.
S25 Ep 147Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. CME information and select publications here.
S25 Ep 146Colorectal Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Dr Christopher Lieu and Dr John Strickler share their perspectives on the evolving therapeutic landscape for patients with colorectal cancer. CME information and select publications here.
S25 Ep 145Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Dr Emmanuel S Antonarakis and Dr Matthew R Smith share their perspectives on the evolving therapeutic landscape for patients with prostate cancer. CME information and select publications here.
S25 Ep 144Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer. CME information and select publications here.
S25 Ep 143Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
S25 Ep 142Endometrial Cancer — Clinical Investigator Perspectives on Actual Patient Cases
Dr Kathleen N Moore from OU Health Stephenson Cancer Center in Oklahoma City, Oklahoma, and Dr Matthew A Powell from the Washington University School of Medicine in St Louis, Missouri, discuss recent updates on available and novel treatment strategies for endometrial cancer. CME information and select publications here.
S25 Ep 141ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer. CME information and select publications here.
S25 Ep 140Colorectal Cancer — An Interview with Dr John Strickler on Molecular Residual Disease Analysis
Dr John Strickler from Duke University in Durham, North Carolina, discusses the measurement of molecular residual disease and its current and potential role in colorectal cancer risk assessment, surveillance and treatment decision-making. CME information and select publications here.
S25 Ep 139Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. CME information and select publications here.
S25 Ep 138Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA
Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia. CME information and select publications here.
S25 Ep 137Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.CME information and select publications here.
S25 Ep 136Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.